Localized gene delivery using antibody tethered adenovirus from polyurethane heart valve cusps and intra-aortic implants

Gene Therapy

Volumn 11, Issue 1, 2004, Pages 15-24

  Stachelek, S J ^a   Song, C ^a   Alferiev, I ^a   Defelice, S ^a   Cui, X ^a   Connolly, J M ^a   Bianco, R W ^a   Levy, R J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Local delivery; Vector

Indexed keywords

ADENOVIRUS VECTOR; AMIDE; BETA GALACTOSIDASE; BROMINE; COLLAGEN; COLLAGEN TYPE 1; DNA; ELASTOMER; GREEN FLUORESCENT PROTEIN; POLYURETHAN; THIOL; VIRUS ANTIBODY;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERY INTIMA; ARTERY MUSCLE; ARTICLE; BALLOON; BLOOD VESSEL GRAFT; BLOOD VESSEL PROSTHESIS; CELL ADHESION; CELL CULTURE; CELL INTERACTION; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; COVALENT BOND; DNA DETERMINATION; EXPERIMENTAL MODEL; EXPLANT; GENE THERAPY; GENETIC TRANSDUCTION; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MATERIAL COATING; MEDICAL RESEARCH; NONHUMAN; POLYMERASE CHAIN REACTION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY VALVE; RAT; SHEEP; SIMULATION; SMOOTH MUSCLE FIBER; STENT; SWINE; VALVULAR HEART DISEASE; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; AORTA; BETA-GALACTOSIDASE; BIOPROSTHESIS; BLOOD VESSEL PROSTHESIS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEART VALVE PROSTHESIS; LUMINESCENT PROTEINS; MALE; POLYURETHANES; PROSTHESIS IMPLANTATION; SHEEP; SWINE;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; OVIS ARIES; SUS SCROFA;

EID: 1642433077     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302129     Document Type: Article

References (27)

1. Grossman PM et al. Incomplete retention after direct myocardial injection. Cath Cardiol Int 2002; 55: 392-397.
2. Sinnaeve P, Varenne O, Collen D, Janssens S. Gene therapy in the cardiovascular system: an update. Cardiol Res 1999; 44: 498-506.
3. Feldman LJ, Tahlil O, Steg PG. Adenovirus-mediated arterial gene therapy for restenosis: problems, perspectives. Semin Int Cardiol 1996; 1: 203-208.
4. Klugherz BD et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000; 18: 1181-1184.
5. Klugherz BD et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002; 13: 443-454.
6. Abrahams JM et al. Endovascular microcoil gene delivery using immobilized anti-adenovirus antibody for vector tethering. Stroke 2002; 33: 1376-1382.
7. Levy RJ et al. Localized adenovirus gene delivery using antiviral IgG complexation. Gene Therapy 2001; 8: 659-667.
8. Alferiev I, Vyavahare N, Song C, Levy R. Elastomeric polyurethanes modified with geminal bisphosphonate groups. J Polym Sci 2001; 39: 105-116.
9. Alferiev I et al. Bisphosphonate derivatized polyurethanes resist calcification. Biomaterials 2001; 22: 2683-2693.
10. Alferiev I et al. Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties. J Biomed Mater Res 2003; 66: 385-395.
11. Bernacca GM. Polyurethane heart valve durability: effects of leaflet thickness and material. J Heart Lung Transpl 1997; 16: 596-599.
12. Bernacca GM. Calcification and stress distribution in bovine pericardial heart valves. Int J Art Org 1992; 15: 284-288.
13. Bernacca GM. In vitro function and durability of a polyurethane heart valve: material considerations. Biomaterials 1996; 17: 1857-1863.
14. Bernacca GM. In vitro blood compatibility of surface-modified polyurethanes. Int J Cardiol 1998; 64: 221-223.
15. Bernacca GM. Surface modification of polyurethane heart valves: effects on fatigue life and calcification. Biomaterials 1998; 19: 1151-1165.
16. Joshi RR, Frautschi JR, Phillips RE, Levy RJ. Phosphonated polyurethanes that resist calcification. J Appl Biomater (New York). 1994; 5: 65-77.
17. Schilling JA. Wound healing. Phys Rev 1968; 48: 374-423.
18. Viljanto J, Rajamaki A. Cellular patterns in the early phase of healing wounds in children. Scand J Plast Reconstr Surg 1976; 10: 83-89.
19. Wheatley DJ. Polyurethane: material for the next generation of heart valve prostheses? Eur J Cardio-Thorac Surg 2000; 17: 355-361.
20. Maillard L, Walsh K. Growth-arrest homeobox gene Gax: a molecular strategy to prevent arterial restenosis. Schweiz Med Wochen J Suisse Med 1996; 126: 1721-1726.
21. Chang MW, Leiden JM. Gene therapy for vascular proliferative disorders. Semin Int Cardiol 1996; 1: 185-193.
22. Morishige K et al. In vivo gene transfer of dominant-negative rho-kinase induces regression of coronary arteriosclerosis in pigs. Ann N Y Acad Sci 2001; 947: 407-411.
23. Kanerva A et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
24. Krasnykh V et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
25. Ebbinghaus C et al. Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter. J Virol 2001; 75: 480-489.
26. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575: 1-14.
27. Wisman CB et al. A polyurethane trileaflet cardiac valve prosthesis: in vitro and in vivo studies. Trans Am Soc Art Int Org 1982; 28: 164-168.